newsfilter
← Latest News
GlobeNewswire·

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at